CTI BioPharma Corp. – Consensus Indicates Potential 132.6% Upside

Broker Ratings

CTI BioPharma Corp. with ticker code (CTIC) now have 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 13 and 4 calculating the average target price we see 7.7. With the stocks previous close at 3.31 this now indicates there is a potential upside of 132.6%. The 50 day MA is 3.37 while the 200 day moving average is 2.66. The company has a market cap of $257m. Find out more information at: http://www.ctibiopharma.com

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index